A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

Hopital Saint-Andre /ID# 224218, Bordeaux

CHU Bordeaux - Hopital Haut Leveque /ID# 224998, Pessac

CHU de Nantes, Hotel Dieu -HME /ID# 215703, Nantes

Gabrail Cancer Center Research /ID# 215667, Canton

Fort Wayne Medical Oncology and Hematology, Inc /ID# 224332, Fort Wayne

CHRU Lille - Hopital Claude Huriez /ID# 217508, Lille

Rambam Health Care Campus /ID# 215808, Haifa

The Chaim Sheba Medical Center /ID# 215810, Ramat Gan

Tel Aviv Sourasky Medical Center /ID# 222749, Tel Aviv

Thomas Jefferson University /ID# 218403, Philadelphia

Centre Antoine Lacassagne - Nice /ID# 218014, Nice

Aichi Cancer Center Hospital /ID# 216469, Nagoya

National Cancer Center Hospital East /ID# 216467, Kashiwa-shi

National Cancer Center Hospital /ID# 216466, Chuo-ku

Oxford University Hospitals NHS Foundation Trust /ID# 217252, Oxford

Cardiff & Vale University Health Board /ID# 217250, Cardiff

The Christie Hospital /ID# 216118, Manchester